Article Text

Download PDFPDF
Exploring life before IBD
  1. Bénédicte De Vroey1,2,
  2. Corinne Gower-Rousseau3,4,
  3. Jean-Frédéric Colombel3,4
  1. 1Department of Gastroenterology, Centre Hospitalier Jolimont, Haine-Saint-Paul, Belgium
  2. 2Department of Gastroenterology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
  3. 3Epidemiology Unit, Université Lille Nord de France, CHU Lille, France
  4. 4Gastroenterology Unit, Université Lille Nord de France, CHU Lille, Hôpital Huriez, Lille, France
  1. Correspondence to Professor Jean-Frederic Colombel, Gastroenterology Unit, Université Lille Nord de France, CHU Lille, Hôpital Huriez, Rue Michel Polonovski, Lille F-59037, France; Jean-Frederic.COLOMBEL{at}CHRU-LILLE.FR

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Van Schaik et al1 present new data on serological markers as predictors of inflammatory bowel diseases (IBD) which open new perspectives on thwarting these diseases at their earliest phase.

The goals of treatment are currently evolving in IBD (ie, Crohn's disease (CD) and ulcerative colitis (UC)) from mere control of symptoms towards prevention of bowel damage and disability. Despite recent evidence for the efficacy of azathioprine and antitumour necrosis factor therapy to decrease the need for surgery, about a third of CD patients still require intestinal resection at 5 years.2 ,3 As in other chronic diseases such as multiple sclerosis and rheumatoid arthritis there is thus an increasing interest in conducting therapeutic trials early in the course of IBD when there is a window of opportunity to modify the natural history of the disease. An international consensus definition of early CD has recently been proposed which includes disease duration of less than 18 months and no previous use of disease-modifying agents.4 This may not be enough and, pushing the paradigm further, the earliest phase at which we may intervene in the …

View Full Text


  • Contributors J-FC developed the outline for the commentary and revised the article; BDV helped develop the outline for the commentary, reviewed the literature and drafted and edited the article; CG-R helped revise the article.

  • Competing interest None.

Linked Articles

  • Inflammatory bowel disease
    Fiona D M van Schaik Bas Oldenburg Andrew R Hart Peter D Siersema Stefan Lindgren Olof Grip Birgit Teucher Rudolf Kaaks Manuela M Bergmann Heiner Boeing Franck Carbonnel Prevost Jantchou Marie-Christine Boutron-Ruault Anne Tjønneland Anja Olsen Francesca L Crowe Petra H M Peeters Martijn G H van Oijen H Bas Bueno-de-Mesquita